262 related articles for article (PubMed ID: 28116591)
21. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
[TBL] [Abstract][Full Text] [Related]
22. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Daily versus Weekly Recording of Gastroesophageal Reflux Disease Symptoms in Patients with a Partial Response to Proton Pump Inhibitor Therapy.
Rydén A; Leavy OC; Halling K; Stone AA
Value Health; 2016; 19(6):829-833. PubMed ID: 27712711
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis.
Man A; Correa JK; Ziemek J; Simms RW; Felson DT; Lafyatis R
Ann Rheum Dis; 2017 Aug; 76(8):1374-1380. PubMed ID: 28213563
[TBL] [Abstract][Full Text] [Related]
25. Value of the Gastroesophageal Reflux Disease Questionnaire (GerdQ) in predicting the proton pump inhibitor response in coronary artery disease patients with gastroesophageal reflux-related chest pain.
He S; Liu Y; Chen Y; Tang Y; Xu J; Tang C
Dis Esophagus; 2016 May; 29(4):367-76. PubMed ID: 25721424
[TBL] [Abstract][Full Text] [Related]
26. What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage).
Vardar R; Keskin M
Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S12-S15. PubMed ID: 29199160
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.
Lipton RB; Gandhi P; Stokes J; Cala ML; Evans CJ; Knoble N; Gelhorn HL; Revicki D; Viswanathan HN; Dodick DW
Headache; 2022 Jan; 62(1):89-105. PubMed ID: 34962305
[TBL] [Abstract][Full Text] [Related]
28. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
[TBL] [Abstract][Full Text] [Related]
29. Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus.
Baldaque-Silva F; Vieth M; Debel M; Håkanson B; Thorell A; Lunet N; Song H; Mascarenhas-Saraiva M; Pereira G; Lundell L; Marschall HU
World J Gastroenterol; 2017 May; 23(17):3174-3183. PubMed ID: 28533674
[TBL] [Abstract][Full Text] [Related]
30. Assessing the impact of lifestyle modification education on knowledge and behavior changes in gastroesophageal reflux disease patients on proton pump inhibitors.
Finley K; Giannamore M; Bennett M; Hall L
J Am Pharm Assoc (2003); 2009; 49(4):544-8. PubMed ID: 19589767
[TBL] [Abstract][Full Text] [Related]
31. Psychometric evaluation of a daily gastro-oesophageal reflux disease symptom measure.
Bytzer P; Reimer C; Smith G; Anatchkova MD; Hsieh R; Wilkinson J; Thomas SJ; Lenderking WR
Scand J Gastroenterol; 2017 Mar; 52(3):276-283. PubMed ID: 27826993
[TBL] [Abstract][Full Text] [Related]
32. [Insufficient symptom control under long-term treatment with PPI in GERD - fact or fiction?].
Labenz J; Labenz G; Stephan D; Willeke F;
MMW Fortschr Med; 2016 May; 158 Suppl 4():7-11. PubMed ID: 27221555
[TBL] [Abstract][Full Text] [Related]
33. Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease.
Jonasson C; Wernersson B; Hoff DA; Hatlebakk JG
Aliment Pharmacol Ther; 2013 Mar; 37(5):564-72. PubMed ID: 23289763
[TBL] [Abstract][Full Text] [Related]
34. Two-year results of intermittent electrical stimulation of the lower esophageal sphincter treatment of gastroesophageal reflux disease.
Rodríguez L; Rodriguez P; Gómez B; Ayala JC; Oxenberg D; Perez-Castilla A; Netto MG; Soffer E; Boscardin WJ; Crowell MD
Surgery; 2015 Mar; 157(3):556-67. PubMed ID: 25726315
[TBL] [Abstract][Full Text] [Related]
35. Patient-reported outcome domains for the esophageal CONDUIT report card: a prospective trial to establish domains.
Lee MK; Yost KJ; Pierson KE; Blackmon SH
Health Qual Life Outcomes; 2018 Oct; 16(1):197. PubMed ID: 30305083
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD.
Mönnikes H; Bardhan KD; Stanghellini V; Berghöfer P; Bethke TD; Armstrong D
Digestion; 2007; 75 Suppl 1():41-7. PubMed ID: 17489031
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
Higginbotham TW
Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
[TBL] [Abstract][Full Text] [Related]
38. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.
Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S
Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281
[TBL] [Abstract][Full Text] [Related]
39. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH.
McCollister D; Shaffer S; Badesch DB; Filusch A; Hunsche E; Schüler R; Wiklund I; Peacock A;
Respir Res; 2016 Jun; 17(1):72. PubMed ID: 27301413
[TBL] [Abstract][Full Text] [Related]
40. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
